HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Yu-Tzu Tai Selected Research

bis(3- bis(4- chlorophenyl)methyl- 4- dimethylaminophenyl)amine

12/2021Promising Antigens for the New Frontier of Targeted Immunotherapy in Multiple Myeloma.
10/2021BCMA-Specific ADC MEDI2228 and Daratumumab Induce Synergistic Myeloma Cytotoxicity via IFN-Driven Immune Responses and Enhanced CD38 Expression.
1/2021Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma.
1/2021Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma.
6/2020BCMA-Targeting Therapy: Driving a New Era of Immunotherapy in Multiple Myeloma.
1/2020A novel BCMA PBD-ADC with ATM/ATR/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma.
11/2019B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma.
1/2019Preclinical assessment of an antibody-PBD conjugate that targets BCMA on multiple myeloma and myeloma progenitor cells.
12/2018SLC46A3 as a Potential Predictive Biomarker for Antibody-Drug Conjugates Bearing Noncleavable Linked Maytansinoid and Pyrrolobenzodiazepine Warheads.
12/2018BCMA CAR T-cell therapy arrives for multiple myeloma: a reality.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Yu-Tzu Tai Research Topics

Disease

128Multiple Myeloma
06/2022 - 02/2002
68Neoplasms (Cancer)
01/2022 - 03/2002
6Hematologic Neoplasms (Hematological Malignancy)
12/2018 - 10/2003
5Waldenstrom Macroglobulinemia (Macroglobulinemia)
12/2016 - 05/2006
4Lymphoma (Lymphomas)
03/2016 - 07/2006
4Chromosomal Instability (Chromosome Stability)
09/2015 - 07/2002
3Bites and Stings (Sting)
12/2021 - 06/2020
3Carcinogenesis
06/2021 - 10/2009
3Genomic Instability
01/2021 - 03/2016
3Monoclonal Gammopathy of Undetermined Significance
03/2013 - 09/2009
2Paraproteinemias (Monoclonal Gammopathy)
03/2016 - 03/2013
2Neoplasm Metastasis (Metastasis)
01/2016 - 07/2015
2Bone Diseases (Bone Disease)
01/2016 - 07/2009
2Bone Resorption
08/2012 - 04/2008
2Severe Combined Immunodeficiency (Bare Lymphocyte Syndrome)
11/2011 - 07/2009
2Plasmacytoma
09/2007 - 07/2007
1Non-Hodgkin Lymphoma (Lymphosarcoma)
10/2021
1Residual Neoplasm
01/2020
1Smoldering Multiple Myeloma
01/2020

Drug/Important Bio-Agent (IBA)

21Monoclonal AntibodiesIBA
12/2021 - 05/2003
15Bortezomib (Velcade)FDA Link
10/2021 - 03/2003
14Proteins (Proteins, Gene)FDA Link
10/2021 - 03/2002
13bis(3- bis(4- chlorophenyl)methyl- 4- dimethylaminophenyl)amineIBA
12/2021 - 05/2014
11Interleukin-6 (Interleukin 6)IBA
10/2021 - 07/2002
10AntigensIBA
12/2021 - 05/2004
10Proteasome InhibitorsIBA
01/2021 - 03/2003
9Lenalidomide (CC 5013)FDA Link
01/2020 - 12/2005
9Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
01/2016 - 02/2002
8Immunomodulating AgentsIBA
01/2021 - 12/2006
7B-Cell Maturation AntigenIBA
12/2021 - 07/2006
7Biological ProductsIBA
01/2020 - 08/2005
7CytokinesIBA
10/2010 - 07/2002
6daratumumabIBA
12/2021 - 02/2011
6Immunoconjugates (Immunoconjugate)IBA
12/2021 - 06/2009
6Pharmaceutical PreparationsIBA
10/2021 - 07/2005
6DNA (Deoxyribonucleic Acid)IBA
01/2021 - 03/2003
5elotuzumabIBA
12/2021 - 08/2008
5Chimeric Antigen ReceptorsIBA
12/2021 - 11/2019
5LigandsIBA
10/2021 - 07/2006
5Messenger RNA (mRNA)IBA
01/2021 - 08/2008
5Histone Deacetylases (Histone Deacetylase)IBA
01/2020 - 10/2003
5Immunoglobulin G (IgG)IBA
03/2013 - 07/2005
4Dexamethasone (Maxidex)FDA LinkGeneric
10/2015 - 07/2005
4MicroRNAs (MicroRNA)IBA
10/2015 - 10/2010
4Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA
03/2012 - 04/2003
3RNA (Ribonucleic Acid)IBA
01/2021 - 10/2003
3pomalidomideIBA
01/2020 - 10/2010
3Complement System Proteins (Complement)IBA
01/2020 - 02/2011
3Transcription Factors (Transcription Factor)IBA
01/2019 - 09/2012
3Histone Deacetylase InhibitorsIBA
01/2018 - 10/2003
3Immunoglobulin M (IgM)IBA
03/2016 - 09/2007
3EnzymesIBA
01/2014 - 10/2003
3InterleukinsIBA
01/2009 - 05/2004
3AntibodiesIBA
01/2008 - 03/2002
3Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA
12/2006 - 09/2002
3Melphalan (Alkeran)FDA LinkGeneric
12/2006 - 03/2003
3NF-kappa B (NF-kB)IBA
07/2006 - 03/2003
3Insulin-Like Growth Factor I (IGF-1)IBA
08/2005 - 02/2003
3Doxorubicin (Adriamycin)FDA LinkGeneric
07/2005 - 03/2002
3Phosphotransferases (Kinase)IBA
12/2004 - 05/2004
2Lysine (L-Lysine)FDA Link
01/2021 - 05/2009
2belantamab mafodotinIBA
01/2021 - 05/2014
2Indicators and Reagents (Reagents)IBA
06/2020 - 01/2018
2Transforming Growth Factor beta (TGF-beta)IBA
01/2020 - 07/2010
2isatuximabIBA
01/2020 - 08/2017
2CD40 Ligand (CD40L)IBA
01/2018 - 07/2005
2Interleukin-10 (Interleukin 10)IBA
08/2017 - 01/2016
2CateninsIBA
01/2017 - 03/2014
2Nicotinamide PhosphoribosyltransferaseIBA
12/2016 - 08/2013
2ibrutinibIBA
12/2016 - 08/2012
2NAD (NADH)IBA
03/2016 - 10/2012
2Tyrosine Kinase InhibitorsIBA
10/2014 - 09/2002
2Agammaglobulinaemia Tyrosine KinaseIBA
08/2013 - 08/2012
2Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA
10/2012 - 05/2004
2Peptides (Polypeptides)IBA
09/2012 - 06/2012
2Aurora Kinase AIBA
06/2010 - 09/2009
2Immunoglobulins (Immunoglobulin)IBA
12/2009 - 03/2002
2perifosineIBA
12/2009 - 07/2007
2beta CateninIBA
09/2009 - 05/2007
2Protein Kinase CIBA
02/2007 - 05/2004
2CaspasesIBA
02/2007 - 12/2004
2dacetuzumabIBA
12/2005 - 04/2004
2Fibronectins (Fibronectin)IBA
07/2005 - 03/2002
2Caveolin 1IBA
10/2004 - 02/2003
2Tyrosine (L-Tyrosine)FDA Link
05/2004 - 05/2004
2Telomerase (Telomerase Reverse Transcriptase)IBA
01/2003 - 07/2002
1nucleotidaseIBA
01/2022
1Membrane Proteins (Integral Membrane Proteins)IBA
01/2022
1Mitochondrial DNA (mtDNA)IBA
06/2021
1CalreticulinIBA
01/2021
1Positive Transcriptional Elongation Factor BIBA
01/2021
1selinexorIBA
01/2021
1Interferon Type IIBA
01/2021
1histone deacetylase 3IBA
01/2020
1Tryptophan (L-Tryptophan)FDA Link
01/2020
1KynurenineIBA
01/2020

Therapy/Procedure

31Therapeutics
06/2022 - 05/2003
14Immunotherapy
01/2022 - 05/2004
3Drug Therapy (Chemotherapy)
01/2021 - 11/2011
2Immunomodulation
12/2021 - 01/2020